BioClonal has officially inaugurated its cutting-edge laboratories in Zaragoza, Spain, marking a major milestone in its mission to combat Alzheimer’s disease. The event, attended by over 50 guests including Aragón’s regional president Jorge Azcón, showcased the company’s groundbreaking work in personalized monoclonal antibody research.
CEO Paula Garfella highlighted BioClonal’s commitment to addressing complex medical challenges, stating, “We aim to transform these challenges into effective solutions that improve patients’ quality of life.” The company is focused on developing innovative diagnostic tools and targeted therapies for Alzheimer’s, leveraging advanced technology to address neuroinflammatory processes.
Founded in late 2022, BioClonal has rapidly gained recognition in the biotechnology sector, winning accolades like the IDEA Award and reaching the finals of the prestigious Emprende XXI competition. With a unique royalty-free business model and a strong emphasis on innovation, the company aspires to become a global leader in immunology and a cornerstone of Aragón’s thriving biotech ecosystem.